What is the appropriate management of hiccups?

Management of Hiccups

For intractable hiccups, chlorpromazine (25-50 mg oral/IM) is the first-line pharmacological treatment, with baclofen (5-10 mg TID) as an alternative first-line option, particularly when long-term therapy is anticipated due to its superior safety profile. 1, 2, 3

Initial Assessment and Simple Interventions

Before pharmacological intervention, attempt physical maneuvers:

• Breath-holding techniques or the HAPI (Hiccup relief using Active Prolonged Inspiration) technique: maximal inspiration held for 30 seconds with continued inspiratory effort and open glottis, followed by slow expiration 4
• Vagal stimulation maneuvers (drinking cold water, swallowing granulated sugar)
• Identify and treat any reversible underlying cause

Pharmacological Management Algorithm

First-Line Agents

For peripheral causes (gastric distension, GERD):

• Metoclopramide 10 mg TID-QID - supported by small randomized controlled trial data 5, 3
• Consider empirical anti-reflux therapy if GERD suspected

For central causes (CNS pathology, metabolic):

• Baclofen 5-10 mg TID (can titrate up to 20 mg TID) - preferred for long-term use due to lower side effect profile 5, 3

Classic first-line (when cause unclear):

• Chlorpromazine 25-50 mg oral or 25 mg IM - historically most studied, though carries higher risk of extrapyramidal symptoms and QTc prolongation 1, 2, 3

Second-Line Agents

If first-line therapy fails after 48-72 hours:

• Gabapentin 300-400 mg TID - good safety profile for long-term use 3
• Haloperidol 1-2 mg oral/IM - effective but monitor for extrapyramidal symptoms 2
• Olanzapine 2.5-10 mg oral - complete resolution reported in case series 2

Palliative Care Setting

For terminal illness or refractory cases:

• Midazolam (subcutaneous infusion) may be appropriate 5

Critical Safety Considerations

When using antipsychotics (chlorpromazine, haloperidol, olanzapine):

• Monitor for QTc prolongation - obtain baseline ECG if using chlorpromazine 1
• Watch for extrapyramidal symptoms (dystonia, akathisia)
• Risk of orthostatic hypotension, particularly with chlorpromazine
• Avoid in patients on other QT-prolonging medications 1
• Consider cardiorespiratory monitoring in high-risk patients

Chlorpromazine-specific warnings:

• Can cause significant hypotension, especially IM route
• Anticholinergic effects may worsen certain conditions
• Most feared complication: torsades de pointes from QTc prolongation 1

Refractory Cases

If pharmacological therapy fails:

• Consider interventional procedures: phrenic nerve block, vagal nerve stimulation 5
• Reassess for underlying treatable causes
• Combination therapy may be necessary (though limited evidence)

Key Clinical Pitfalls

• Don't dismiss persistent hiccups - they profoundly impact quality of life and may indicate serious underlying pathology 5
• Don't use chlorpromazine as monotherapy long-term without considering baclofen or gabapentin alternatives due to side effect burden 3
• Don't forget to check for drug interactions - many antipsychotics interact with commonly used medications 1
• Don't overlook GERD as a treatable cause - empirical PPI trial is reasonable 3

Evidence Quality Note

The evidence base remains limited - no adequately powered randomized controlled trials exist 3. Treatment recommendations are based on small RCTs (baclofen, metoclopramide), case series, and observational data. The 2016 Pediatrics guideline mentions chlorpromazine for intractable hiccups, supporting its established role 1. The most recent systematic review (2026) confirms chlorpromazine and olanzapine effectiveness but emphasizes need for better controlled trials 2.